It has been hypothesized that inhibition of cytokine signaling could impair clearance of SARS-CoV-2, and result in worse outcomes such as secondary infections; this has been previously observed in the treatment of influenza [138] and subsequent to the use of IL-6 inhibitors in COVID-19 patients [133]. This evidence concerns the gene IL6 and COVID-19.